ESMO 2019 | Preliminary findings in mCRPC for fractionated dose 177Lu-PSMA-617

Scott Tagawa

Scott Tagawa, MD, MS, Weill Cornell Medicine, New York, NY, discusses the initial findings of the trial of fractionated dose 177Lu-PSMA-617 for progressive metastatic castration resistant prostate cancer (mCRPC; NCT03042468). This interview took place at the European Society for Medical Oncology (ESMO) 2019 congress in Barcelona, Spain.

Share this video